Clinical Potential of HER2 PET as a Predictive Biomarker to Guide the Use of Trastuzumab Deruxtecan in Breast Cancer Patients

J Nucl Med. 2023 Jul;64(7):1164-1165. doi: 10.2967/jnumed.123.265434. Epub 2023 May 25.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Biomarkers
  • Breast Neoplasms* / diagnostic imaging
  • Breast Neoplasms* / drug therapy
  • Camptothecin
  • Female
  • Humans
  • Immunoconjugates*
  • Positron-Emission Tomography
  • Receptor, ErbB-2
  • Trastuzumab / therapeutic use

Substances

  • trastuzumab deruxtecan
  • Trastuzumab
  • Camptothecin
  • Immunoconjugates
  • Biomarkers
  • Receptor, ErbB-2